Core Viewpoint - The company's positive profit forecast for 2025 aligns with expectations, maintaining a "Buy" rating with a target price of HKD 75 [1] Group 1: Financial Performance - The company anticipates a revenue growth of over 45% year-on-year for 2025, with gross profit expected to grow over 70% year-on-year and net profit attributable to shareholders projected to increase by over 38% year-on-year [1] - Adjusted net profit, excluding interest income and expenses, is expected to grow over 45% year-on-year, and over 65% year-on-year when excluding foreign exchange impacts [1] - The overall revenue and net profit attributable to shareholders are in line with previous expectations and the company's annual guidance [1] Group 2: Project Development - The company signed 70 new iCMC projects in 2025, accelerating from 53 in 2024, primarily driven by strong growth in the US and China [2] - More than half of the new iCMC projects are attributed to new ADC types, with approximately 20% from dual-antibody ADCs, 17% from XDC, and 10% from non-tumor areas [2] Group 3: Long-term Guidance - The company has disclosed a medium to long-term revenue guidance, expecting a CAGR of 30-35% from 2025 to 2030, surpassing the industry average of 25.6% CAGR [3] - By 2030, it is projected that 20% of revenue will come from XDC types and another 20% from commercialized projects [3] - The company anticipates achieving significant commercial production milestones starting in 2027, with limited revenue contribution expected in 2026 [3] Group 4: Capacity Expansion - The company plans to increase capital expenditure to RMB 1.7 billion in 2026, up from RMB 1.22 billion in 2025, with a long-term capital expenditure guidance exceeding RMB 7 billion by 2029 [4] - The company has established dual production bases in China and Singapore, with the Wuxi DP3 capacity achieving GMP release in July 2025, totaling 7 million bottles per year [4] - Future production lines in Wuxi are expected to double the DP capacity before 2029 [4] Group 5: Strategic Acquisitions - The company is actively pursuing acquisitions to enhance capacity, including a recent acquisition in Hefei to add over 40 kg of peptide conjugate capacity and another acquisition of Dongyao Pharmaceutical for HKD 3.1 billion to add 8 million bottles per year of DP capacity [5] - The company’s global ADC outsourcing market share has reached over 24% [5] Group 6: Valuation - The company maintains a "Buy" rating with a target price of HKD 75, based on updated revenue forecasts for 2025E/2026E/2027E of RMB 5.87 billion, RMB 7.94 billion, and RMB 10.59 billion respectively [6] - Adjusted net profit forecasts are slightly revised to RMB 1.6 billion, RMB 2.12 billion, and RMB 2.91 billion for the same years [6] - The target valuation is set at 38x 2026E PE, reflecting a premium over the historical forward P/E ratio [6]

Investment Rating - The report maintains a "Buy" rating for WuXi AppTec (2268.HK) with a target price of HKD 75, indicating a potential upside of 24% from the current price of HKD 60.6 [1][2][11]. Core Insights - The company's preliminary earnings forecast for 2025 aligns with expectations, projecting over 45% year-on-year revenue growth, over 70% gross profit growth, and over 38% net profit growth attributable to shareholders [8][11]. - WuXi AppTec has signed 70 new iCMC projects in 2025, benefiting from strong growth in the US and China, with over half of these projects coming from new ADC contributions [8][11]. - The company has provided a long-term revenue guidance of a 30-35% CAGR from 2025 to 2030, which is above the industry average of 25.6% CAGR [8][11]. Financial Performance - Revenue projections for 2025, 2026, and 2027 are adjusted to RMB 58.7 billion, RMB 79.4 billion, and RMB 105.9 billion respectively, with net profit estimates of RMB 16.0 billion, RMB 21.2 billion, and RMB 29.1 billion [11][12]. - The gross margin for 2025 is expected to be approximately 35.8%, which is better than previous expectations [8][11]. - The company anticipates significant commercial revenue starting in 2027, with limited contributions expected in 2026 as it focuses on building commercial production records [8][11]. Capacity Expansion - WuXi AppTec is accelerating capacity expansion through both self-built facilities and acquisitions, with capital expenditures expected to rise to RMB 1.7 billion in 2026 from RMB 1.22 billion in 2025 [2][10]. - The company has established dual production bases in China and Singapore, with plans for further expansion, including new production lines in Wuxi and Singapore [2][10]. - The acquisition of Hefei and Dongyao Pharmaceutical is expected to enhance the company's production capacity and client network, contributing to a market share of over 24% in the global ADC outsourcing market [10][11].

Investment Rating - The report maintains a "Buy" rating for WuXi AppTec (2268.HK) with a target price of HKD 75, indicating a potential upside of 24% from the current price of HKD 60.6 [1][2][11]. Core Insights - The company's preliminary earnings forecast for 2025 shows revenue growth exceeding 45% year-on-year, with gross profit growth over 70% and net profit growth exceeding 38% [8][11]. - WuXi AppTec has signed 70 new iCMC projects in 2025, benefiting from strong growth in the US and China, with over half of these projects coming from new ADC contributions [8][11]. - The company has provided a long-term revenue guidance of a 30-35% CAGR from 2025 to 2030, which is above the industry average of 25.6% CAGR [8][11]. Financial Performance - Revenue projections for 2025, 2026, and 2027 are adjusted to RMB 58.7 billion, RMB 79.4 billion, and RMB 105.9 billion respectively, with net profit estimates of RMB 16.0 billion, RMB 21.2 billion, and RMB 29.1 billion [11][12]. - The gross margin for 2025 is expected to be around 35.8%, which is better than previous expectations [8][11]. - The company anticipates significant commercial revenue starting in 2027, with limited contributions expected in 2026 as it focuses on accumulating production records [8][11]. Capacity Expansion - WuXi AppTec is accelerating capacity expansion through both self-built facilities and acquisitions, with capital expenditures expected to rise to RMB 1.7 billion in 2026 from RMB 1.22 billion in 2025 [2][10]. - The company has established dual production bases in China and Singapore, with plans for further expansion, including new DP production lines in Wuxi and a new facility in Singapore expected to achieve GMP release in 2026 [2][10]. - The company has a global market share of over 24% in the ADC outsourcing service market, indicating a strong competitive position [10].

Core Viewpoint - The company has demonstrated robust growth in the first half of 2025, with significant increases in revenue, gross profit, and net profit, driven by a strong order backlog and competitive positioning in the ADC market [1][2]. Financial Performance - In H1 2025, the company achieved revenue of 2.7 billion yuan, a year-on-year increase of 62.2% - Gross profit reached 980 million yuan, up 82.2% year-on-year - Adjusted net profit (excluding interest and expenses) was 730 million yuan, reflecting a 69.6% increase year-on-year - Adjusted net profit (including interest income and expenses) stood at 800 million yuan, a 50.1% year-on-year growth - Reported net profit was 750 million yuan, marking a 52.7% increase year-on-year [1]. Order Backlog and Market Position - As of H1 2025, the company had an unfulfilled order total of 1.33 billion USD, a year-on-year increase of 57.9% - New contract amounts grew by 48.4% year-on-year, with North America showing the highest growth rate - The global ADC market is projected to reach 13.2 billion USD in 2024, with a compound annual growth rate (CAGR) of 34.0% from 2020 to 2024, and expected to grow to 66.2 billion USD by 2030, with an outsourcing rate of approximately 60% [1][2]. Market Share and Competitive Advantage - The company's market share in the ADC sector increased from 9.9% in 2022 to 22.2% in H1 2025 - The company collaborates with 13 out of the top 20 global pharmaceutical companies, reinforcing its leading position in the industry [1][2]. Strategic Expansion and Capital Expenditure - In H1 2025, the company signed 37 new iCMC projects, including 13 winning molecule projects, and added 3 new PPQ projects - The company plans to invest approximately 1.56 billion yuan in capital expenditures in 2025, with around 900 million yuan allocated to the Singapore base and about 450 million yuan to the Wuxi base - Total capital expenditures are expected to exceed 7 billion yuan by 2029, with new capacities including coupling raw liquids, coupling formulations, and payload linkers [2]. Investment Outlook - The company is positioned as a leader in the rapidly expanding ADC CXO industry, with strong technical capabilities and product delivery quality - Revenue forecasts for 2025-2027 are projected at 5.99 billion yuan, 8.24 billion yuan, and 10.51 billion yuan, representing year-on-year growth rates of 47.7%, 37.7%, and 27.5% respectively - Net profit forecasts for the same period are 1.51 billion yuan, 2.06 billion yuan, and 2.67 billion yuan, with growth rates of 41.5%, 36.2%, and 29.4% respectively [2].

Investment Rating - The investment rating for the company is "Buy" (maintained) [7] Core Insights - The company achieved a significant revenue growth of 62.2% year-on-year, reaching 2.7 billion yuan in the first half of 2025. The gross profit increased by 82.2% to 980 million yuan, and the adjusted net profit (excluding interest and expenses) rose by 69.6% to 730 million yuan [5][11] - The company has a robust order backlog of 1.33 billion USD, reflecting a year-on-year increase of 57.9%, with new contract signings growing by 48.4% [11] - The global ADC market is projected to reach 13.2 billion USD in 2024, with a compound annual growth rate (CAGR) of 34.0% from 2020 to 2024, and is expected to grow rapidly to 66.2 billion USD by 2030 [11] - The company’s market share in the ADC outsourcing service sector has increased from 9.9% in 2022 to 22.2% in the first half of 2025, solidifying its position as an industry leader [11] Financial Performance - For the first half of 2025, the company reported revenues of 2.7 billion yuan, with a gross profit of 980 million yuan and a net profit of 750 million yuan [5][11] - The company forecasts revenues of 5.99 billion yuan, 8.24 billion yuan, and 10.51 billion yuan for 2025, 2026, and 2027, respectively, with year-on-year growth rates of 47.7%, 37.7%, and 27.5% [13][14] - The adjusted net profit is expected to be 1.51 billion yuan, 2.06 billion yuan, and 2.67 billion yuan for the same years, with growth rates of 41.5%, 36.2%, and 29.4% [13][14] Capital Expenditure and Expansion - The company plans to invest approximately 1.56 billion yuan in capital expenditures in 2025, with significant investments in its Singapore and Wuxi bases [12] - By 2029, total capital expenditures are expected to exceed 7 billion yuan, aimed at expanding production capacity for various ADC-related products [12]